- Home
- EXAS
as 07-26-2024 4:00pm EST
Exact Sciences Corporation, headquartered in Madison, Wisconsin, provides cancer screening and diagnostic test products in the United States and internationally. Exact's Cologuard screening test, a noninvasive stool-based DNA test, is a pre-cancer screening test for colorectal cancer. The company also competes in the precision oncology market with Oncotype DX, a suite of tissue-based genomic tests for estimating recurrence risk and likelihood of benefit from chemotherapy for breast and colon cancer, and OncoExTra, a liquid-based comprehensive genomic profiling test. It is developing liquid biopsy tests for molecular residual disease, colorectal cancer screening, and multicancer screening, too.
Upcoming Earnings Alert:
Get ready for potential market movements as Exact Sciences Corporation EXAS prepares to release earnings report on 31 Jul 2024.
| Founded: | 1995 | Country: | United States |
| Employees: | N/A | City: | MADISON |
| Market Cap: | 9.2B | IPO Year: | N/A |
| Target Price: | $85.92 | AVG Volume (30 days): | 2.4M |
| Analyst Decision: | Strong Buy | Number of Analysts: | 14 |
| Dividend Yield: | N/A | Dividend Payout Frequency: | N/A |
| EPS: | -1.32 | EPS Growth: | N/A |
| 52 Week Low/High: | $40.62 - $99.56 | Next Earning Date: | 07-31-2024 |
| Revenue: | $2,534,840,000 | Revenue Growth: | 15.21% |
| Revenue Growth (this year): | 15.49% | Revenue Growth (next year): | 13.68% |
Stock Insider Trading Activity of Exact Sciences Corporation (EXAS)
| Name | Ticker | Relationship | Date | Transaction | Cost Per Share | Shares | Total Value | Securities Owned After Transaction(s) | SEC Form 4 |
|---|---|---|---|---|---|---|---|---|---|
| ORVILLE JACOB A | EXAS | General Manager, Screening | Apr 30 '24 | Sell | $60.15 | 102 | $6,135.30 | 14,440 | SEC Form 4 |
| Conroy Kevin T | EXAS | President and CEO | Apr 30 '24 | Sell | $60.15 | 1,155 | $69,473.25 | 1,156,191 | SEC Form 4 |
| Condella Sarah | EXAS | EVP, Human Resources | Apr 30 '24 | Sell | $60.15 | 102 | $6,135.30 | 72,611 | SEC Form 4 |
| Herriott James | EXAS | SVP, General Counsel & Sec | Apr 30 '24 | Sell | $60.15 | 30 | $1,804.50 | 9,866 | SEC Form 4 |
| COWARD D SCOTT | EXAS | Director | Apr 30 '24 | Sell | $60.15 | 67 | $4,030.05 | 44,644 | SEC Form 4 |
| Cunningham Everett | EXAS | Chief Commercial Officer | Apr 30 '24 | Sell | $60.15 | 136 | $8,180.40 | 47,042 | SEC Form 4 |
| Elliott Jeffrey Thomas | EXAS | Chief Financial Officer | Apr 30 '24 | Sell | $60.15 | 136 | $8,180.40 | 11,795 | SEC Form 4 |
| Baranick Brian | EXAS | EVP, GM., Precision Oncology | Apr 30 '24 | Sell | $60.15 | 110 | $6,616.50 | 13,279 | SEC Form 4 |
| Baranick Brian | EXAS | EVP, GM., Precision Oncology | Apr 2 '24 | Sell | $79.43 | 924 | $73,393.32 | 13,171 | SEC Form 4 |
| Condella Sarah | EXAS | EVP, Human Resources | Apr 1 '24 | Sell | $70.00 | 2,000 | $140,000.00 | 71,787 | SEC Form 4 |
| Condella Sarah | EXAS | EVP, Human Resources | Mar 28 '24 | Sell | $70.00 | 2,000 | $140,000.00 | 73,787 | SEC Form 4 |
| Doyle James Edward | EXAS | Director | Mar 1 '24 | Sell | $57.50 | 2,000 | $115,000.00 | 50,110 | SEC Form 4 |
| LEVANGIE DANIEL J | EXAS | Director | Mar 1 '24 | Sell | $57.50 | 5,000 | $287,500.00 | 22,975 | SEC Form 4 |
| Herriott James | EXAS | General Counsel | Feb 29 '24 | Sell | $59.32 | 862 | $51,133.84 | 9,125 | SEC Form 4 |
| Elliott Jeffrey Thomas | EXAS | Chief Financial Officer | Feb 29 '24 | Sell | $59.32 | 2,412 | $143,079.84 | 10,933 | SEC Form 4 |
| Cunningham Everett | EXAS | Chief Commercial Officer | Feb 29 '24 | Sell | $59.32 | 2,412 | $143,079.84 | 46,179 | SEC Form 4 |
| Baranick Brian | EXAS | Gen. Mgr., Precision Oncology | Feb 29 '24 | Sell | $59.32 | 2,323 | $137,800.36 | 14,095 | SEC Form 4 |
| ORVILLE JACOB A | EXAS | General Manager, Screening | Feb 29 '24 | Sell | $59.32 | 2,154 | $127,775.28 | 14,324 | SEC Form 4 |
| Conroy Kevin T | EXAS | President and CEO | Feb 29 '24 | Sell | $59.32 | 8,271 | $490,635.72 | 1,299,496 | SEC Form 4 |
| Condella Sarah | EXAS | EVP, Human Resources | Feb 29 '24 | Sell | $59.32 | 1,724 | $102,267.68 | 75,787 | SEC Form 4 |
| Baranick Brian | EXAS | Gen. Mgr., Precision Oncology | Feb 26 '24 | Sell | $56.89 | 2,027 | $115,316.03 | 11,694 | SEC Form 4 |
| Cunningham Everett | EXAS | Chief Commercial Officer | Feb 26 '24 | Sell | $56.89 | 3,648 | $207,534.72 | 43,300 | SEC Form 4 |
| Condella Sarah | EXAS | EVP, Human Resources | Feb 26 '24 | Sell | $56.89 | 1,880 | $106,953.20 | 73,732 | SEC Form 4 |
| Conroy Kevin T | EXAS | President and CEO | Feb 26 '24 | Sell | $56.89 | 6,263 | $356,302.07 | 1,289,624 | SEC Form 4 |
| ORVILLE JACOB A | EXAS | General Manager, Screening | Feb 26 '24 | Sell | $56.89 | 1,879 | $106,896.31 | 11,754 | SEC Form 4 |
Latest Exact Sciences Corporation News
EXAS Breaking Stock News: Dive into EXAS Ticker-Specific Updates for Smart Investing
Zacks
a day ago
Blueprint Medicines (BPMC) Expected to Beat Earnings Estimates: Should You Buy?
Zacks
2 days ago
Exact Sciences (EXAS) May Report Negative Earnings: Know the Trend Ahead of Next Week's Release
Insider Monkey
11 days ago
Exact Sciences Corporation (EXAS) Slipped Over Investors’ Concerns
Medical Device Network
16 days ago
Geneoscopy’s ColoSense deemed reliable in published study
Motley Fool
18 days ago
This Cathie Wood Growth Stock Could Soar by 93%, According to Wall Street
Business Wire
19 days ago
Exact Sciences schedules second quarter 2024 earnings call
The Wall Street Journal
20 days ago
People Are Feeling Stuck in Their Jobs. Bosses Are Starting to Worry.
MT Newswires
a month ago
Scotiabank Initiates Exact Sciences at Sector Outperform With $70 Price Target
Compare EXAS vs Leading Stocks
Share on Social Networks:
Disclaimer
The information presented on this page, "EXAS Exact Sciences Corporation - Stocks Price | History | Analysis", including historical data, forecasts, news, insider information, and predictions, is provided for educational purposes only. It should not be considered as financial advice or a recommendation to buy or sell any securities. Decisions regarding investments should be made only after careful consideration and consultation with a qualified financial advisor. We do not endorse or guarantee the accuracy or reliability of the information provided, and we disclaim any liability for financial losses incurred as a result of decisions made based on the information presented.